FDA OKs Biologic Guselkumab (Tremfya) for Plaque Psoriasis

Guselkumab is the first and only approved biologic agent that selectively blocks interleukin-23, a key player in plaque psoriasis.
FDA Approvals

http://ift.tt/2tbOtoU